Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT03620890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03620890
Main results
  • Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial American journal of obstetrics and gynecology, 2021-07 DOI, PubMed 33865836

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03620890. Randomized; no masking; primary purpose treatment. Start 2018-09-04 (actual); primary completion 2020-07-29 (actual). Results posted on 2021-08-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
Acronym
Determin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Neutral Protamine Hagedorn (NPH)
Intervention (Drug)
Detemir insulin
Lead sponsor
The University of Texas Health Science Center, Houston (class: other)

Record details

Record id
cardio:ct-nct03620890
Content hash
afa6b86c3dbf6b6b3bcea39013650f9e6a7ba0e841d4f70c3d81f232037aca1a